TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01827332

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
Study: NCT02391961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
Study: NCT04327089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Nox 1/4 inhibitor
Study: NCT01811615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol-free experimental mouth rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol-free experimental mouth rinse

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: alcohol-containing mouth rinsing
Study: NCT02205333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6469 plus Rituximab
Description: MEDI6469 in combination with Rituximab
Study: NCT00134160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan medoxomil
Description: Olmesartan medoxomil 40mg/Day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium channel blockers (amlodipine, azelnidipine)
Description: Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
Study: NCT01187927

Intervention type: BIOLOGICAL
Intervention: Cervarix®
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study: NCT02548247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orafti® Inulin
Description: Dietary fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT01413555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Culture QI Program
Description: The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
Study: NCT00674453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: Oral tablet, 0.25 mg, daily, 2 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet given once daily for 2 years
Study: NCT01471106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Group 1: 40 mg by mouth once a day.~Group 2: 80 mg by mouth once a day.
Study: NCT04481633

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID 19 serology
Description: Diagnosis of Covid-19 past infection will be made by serology

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: COVID 19 serology
Description: Diagnosis of Covid-19 past infection will be made by serology

Intervention type: OTHER
Group type: OTHER
Intervention: COVID 19 Self-Questionnaire
Description: COVID 19 Self-Questionnaire

Intervention type: OTHER
Group type: OTHER
Intervention: COVID 19 Self-Questionnaire
Description: COVID 19 Self-Questionnaire
Study: NCT03774433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laddr
Description: Laddr is an integrated, personalized, web-based self-regulation assessment and behavior change system. It integrates tools that have been shown to be effective for a wide array of behavioral phenomena ranging from substance use and abuse, mental health, risk-taking, chronic pain management, medication adherence, diet, exercise, diabetes and other chronic disease management, and smoking. The organizational structure, functionality and content within Laddr's system centrally embrace these fundamental aspects of behavior change; thus, the Laddr platform is not diagnosis-specific but rather enables integrated care for any combination of individuals' goals, needs, and preferences.
Study: NCT00368654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initial dose 5 mg, then 15 mg per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Initial dose 5 mg, then 15 mg per week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
Study: NCT00984243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PHOTODYNAMIC THERAPY (PDT)
Description: Photodynamic Procedure:~Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.~It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.~Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens~Energy density:~Argon-dye laser: 200-300 Joules/cm\^2 Excimer-dye laser: 100-200 Joules/cm\^2
Study: NCT03795311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX Bevacizumab
Description: In phase 1, the goal is to define the DLT (maximum tolerated dose). 3 levels of doses will be evaluated with a different dose of irinotecan in each level.~* Level -1: Bevacizumab + Oxaliplatine + Acide folinique + Irinotecan: 60mg / m2~* Level 0: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 70mg / m2~* Level 1: Bevacizumab + Oxaliplatine + Acide folinique +Irinotecan: 90mg / m2~The inclusion of patients will start at level 0. Dose-limiting toxicities will be identified during the first 2 cycles.
Study: NCT00930566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxsalen
Description: UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.~In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :~Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracoporal Photopheresis (ECP)
Description: In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.~After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient.
Study: NCT02796040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study: NCT01337219

Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin

Intervention type: DRUG
Group type: OTHER
Intervention: Tobramycin
Study: NCT05196542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape
Description: comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure

Intervention type: PROCEDURE
Group type: OTHER
Intervention: patients with apical prolapse who will do Sacro hysteropexy using mersilene tape
Description: comparison between standard poly prolene mesh and the poly ester mersilene tape in Sacro hysteropexy surgical procedure
Study: NCT03343873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam was administered intravenously at a dose of 0.1 mg / kg followed by continuous intravenous injection at 0.03 mg / kg / h and maintained until the course of the scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol group 1mg / kg intravenous injection, followed by 2mg / kg / h continuous intravenous injection, and maintained to the scanning process;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine group with total amount of 1μg / kg, infusion time 15min, followed by 0.6μg / kg / h, and maintained to the scanning process;
Study: NCT01092182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-R
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-R
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-RR
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (EPOCH-R) every 21 days for 3 cycles
Study: NCT01348555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilatator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bronchodilatator
Study: NCT03226977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
Study: NCT04560894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT-I10A
Description: Participants receive SCT-I10A intravenously，200mg，d1，Q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510
Description: Participants receive SCT510 intravenously，15mg/kg，d1，Q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib 200mg
Description: Participants receive sorafenib orally，400mg bid
Study: NCT02308488

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Description: Patients will receive 15 daily radiation fractions of 2.7 Gy, Monday to Friday for three weeks, to the entire breast/chest wall and axillary level III and supraclavicular nodes with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7 Gy + 0.5 Gy). The overall dose will be 40.5 Gy to the breast/chest wall, axillary level III and supraclavicular nodes, and 48.0 Gy to the tumor bed.
Study: NCT00645463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: 20 mg CP-945,598 + 240 mg MR Diltiazem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: 20 mg CP-945,598 alone
Study: NCT03759470

Intervention type: DIAGNOSTIC_TEST
Intervention: CSF examination
Description: The CSF samples will be stored at -80°C until testing . CSF specimens will be prepared for GS and culture examinations by centrifugation at 3,000 rpm for 10 minutes at room temperature. Culture will be performed by inoculating 1-2 drops of CSF sediment directly onto each of the following agar plates: horse-blood agar, Thayer-Martin agar, choc- olate agar and Sabouraud agar. Moreover, a broth tube (brain-heart infusion, BHI) will be inoculated with one drop of the sediment. Agar plates and broth will be incubated for 1 to 5 days at 35-37°C (with \~5% CO2, or in a candle-jar, for Thayer-Martin and chocolate agar) .~In addition to GS and culture method , India ink test and culture and latex agglutination test (LAT). LAT assay will be performed on CSF samples using Latex-antigen detection system kit.
Study: NCT04705948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate versus ketamine
Description: Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate versus ketamine
Description: Magnesium sulfate versus ketamine for of post-operative sore throat after endotracheal intubation
Study: NCT02235103

Intervention type: OTHER
Intervention: Sperm Chromatin Dispersion Test

Intervention type: OTHER
Intervention: Sperm Chromatin Dispersion Test
Study: NCT02754960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
Study: NCT03933176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of carious lesions
Description: Selective carious tissue removal followed by restoration of the cavity using composite resin.
Study: NCT01657903

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Fluoride
Description: Toothpaste containing 1450 ppm F - EU level as NaF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride
Description: Toothpaste containing 1450 ppm F - EU level as NaF.
Study: NCT03933176

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration of carious lesions
Description: Selective carious tissue removal followed by restoration of the cavity using composite resin.
Study: NCT02439567

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan: Liver and Spleen elastography
Description: In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
Study: NCT00002807

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 45 Gy in 25 fractions over 5 weeks
Study: NCT01929538

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered self-expanding biliary metal stent, 12mm in diameter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered self-expanding biliary metal stent, 10mm in diameter
Study: NCT00544284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02117999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cross-linking with iontophoresis
Description: The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard corneal cross-linking
Description: In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
Study: NCT01581307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)
Description: The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSpheres
Description: TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
Study: NCT02081079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study: NCT02182531

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pseudoephedrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine + Pseudoephedrine combination

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinastine + Pseudoephedrine combination

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinastine + Pseudoephedrine combination
Study: NCT04395209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assesment
Description: muscle strength assessment in stroke individuals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: assesment
Description: muscle strength assessment in stroke individuals
Study: NCT00657007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 1. 1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).~2. 1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 1. 4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).~2. 4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 1. 10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).~2. 10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: belimumab
Description: 1. 20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).~2. 20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. IV (in the vein) on Day 0 (Cohorts 1-4).~2. IV (in the vein) on Days 0 and 21 (Cohorts 5-8).
Study: NCT00878709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04563169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video consultation
Description: The first video consultation with a nurse was planned one week after start with CPAP. Three focus points were discussed during the consultations: 1) adherence (\>6 hours per night); 2) rest AHI \< 5 (or \<10 if age \>70), and 3) (improvements in) complaints. If these objectives were achieved after one week, a new consultation was planned three weeks later (four weeks after start). As long as these objectives were not achieved, video consultations were planned weekly (until after four weeks).
Study: NCT03456596

Intervention type: OTHER
Intervention: ENABLE
Description: This is an implementation science study in which an evidence-based early palliative care intervention, ENABLE (Educate, Nurture, Advise, Before Life Ends), is being implemented in rural community cancer centers that did not have a palliative care program.
Study: NCT03238638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epacadostat
Description: Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
Study: NCT01831154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tight Glycemic
Description: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional Glycemic
Description: The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Glycemic
Description: Insulin was Regular Insulin administered intravenous bolus.